User profiles for "author:Rangi Kandane-Rathnayake"

Rangi Kandane-Rathnayake

Senior Researcher, Monash University
Verified email at monash.edu
Cited by 1559

[HTML][HTML] Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international Taskforce

K Connelly, LE Eades, R Koelmeyer, D Ayton… - Nature Reviews …, 2023 - nature.com
Systemic lupus erythematosus (SLE) is a disease of high unmet therapeutic need. The
challenge of accurately measuring clinically meaningful responses to treatment has …

[HTML][HTML] Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study

V Golder, R Kandane-Rathnayake, AYB Hoi… - Arthritis research & …, 2017 - Springer
Background Systemic lupus erythematosus (SLE) is associated with significant impairment
of health-related quality of life (HR-QoL). Recently, meeting a definition of a lupus low …

Clinician-reported outcome measures in lupus trials: a problem worth solving

K Connelly, V Golder… - The Lancet …, 2021 - thelancet.com
Systemic lupus erythematosus (SLE) remains a disease of high unmet clinical need.
Because of substantial patient heterogeneity, the execution of clinical trials that successfully …

[HTML][HTML] Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus

R Mende, FB Vincent, R Kandane-Rathnayake… - Frontiers in …, 2018 - frontiersin.org
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease
characterized by biological and clinical heterogeneity. The interleukin (IL)-1 superfamily is a …

[HTML][HTML] Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus

J Godsell, I Rudloff, R Kandane-Rathnayake, A Hoi… - Scientific reports, 2016 - nature.com
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by
the development of autoantibodies to nuclear antigens and inflammatory responses …

Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study

V Golder, R Kandane-Rathnayake, M Huq… - The Lancet …, 2019 - thelancet.com
Background Treat-to-target strategies have improved outcomes in single-organ diseases
with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented …

Independent association of glucocorticoids with damage accrual in SLE

D Apostolopoulos, R Kandane-Rathnayake… - Lupus science & …, 2016 - lupus.bmj.com
Objectives To determine factors associated with damage accrual in a prospective cohort of
patients with SLE. Methods Patients with SLE who attended the Lupus Clinic at Monash …

Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort …

R Kandane-Rathnayake, V Golder… - The Lancet …, 2022 - thelancet.com
Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …

[HTML][HTML] 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

R Kandane-Rathnayake, W Louthrenoo, A Hoi… - Arthritis Research & …, 2022 - Springer
Background The unmet need in systemic lupus erythematosus (SLE) with the current
standard of care is widely recognised, but few studies have quantified this. The recent …

Adherence to asthma management guidelines by middle-aged adults with current asthma

RK Kandane-Rathnayake, MC Matheson, JA Simpson… - Thorax, 2009 - thorax.bmj.com
Background: With the increasing burden of asthma worldwide, much effort has been given to
developing and updating management guidelines. Using data from the Tasmanian …